Results 41 to 50 of about 12,797 (181)
Management of trypanosomiasis and leishmaniasis [PDF]
<p>Background: The current treatments for human African trypanosomiasis (HAT), Chagas disease and leishmaniasis (collectively referred to as the kinetoplastid diseases) are far from ideal but, for some, there has been significant recent progress ...
Alsford +39 more
core +2 more sources
This study describes unpublished research on improving the solubility of benznidazole by the formation of an inclusion complex. The cyclodextrins selected were αCD, βCD, γCD, HPβCD, RMβCD and SBβCD. All complexes were obtained in solution, presenting 1:1
José Lamartine Soares Sobrinho +4 more
doaj +1 more source
A gram‐scale supply of bulbiferamide A, which features a rare N‐acylindole linkage and possesses potent inhibitory activity against Trypanosoma cruzi epimastigotes (IC50 = 4.1 µM)—the causative parasite of Chagas disease—was successfully achieved. Moreover, the cyclization strategy developed in this study facilitated the synthesis of noncanonical ...
Jie Zhang, Hugh Nakamura
wiley +1 more source
Impact of migration on the occurrence of new cases of Chagas disease in Buenos Aires city, Argentina [PDF]
Chagas disease, also known as American Trypanosomiasis, is endemic in the Americas, especially Central and South America. Chagas disease is a zoonotic disease caused by the parasite Trypanosoma cruzi.
Altcheh, Jaime Marcelo +12 more
core +2 more sources
Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study
Neglected tropical diseases (NTDs) remain a major global health challenge, particularly in low‐ and middle‐income countries. Kinetoplastid parasites causing Chagas disease, leishmaniasis, and African trypanosomiasis rely on host purine salvage pathways, making nucleoside analogues attractive therapeutic candidates.
Silvester Lowe +6 more
wiley +1 more source
In vitro and in vivo experimental models for drug screening and development for Chagas disease
Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Although the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still ...
Alvaro José Romanha +24 more
doaj +1 more source
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
Chagas disease (CD) is a parasitic zoonosis endemic in Central and South America affecting nearly 10 million people, with 100 million people at high risk of contracting the disease.
Miriam Rolon +6 more
doaj +1 more source
Repurposing of Inhibitors of Plasmodial Aspartate Transcarbamoylase Toward Trypanosoma Cruzi
Aspartate transcarbamoylase (ATC) catalyzes the committed and rate‐limiting step in the pyrimidine de novo biosynthesis pathway. While previously suggested to be a potential target for antimalarial, antitubercular, and antioncologic drug discovery, we hypothesized that an existing compound library of ATC inhibitors designed from one scaffold by ...
Siyao Chen +8 more
wiley +1 more source
Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure [PDF]
Chagas disease is a neglected tropical affection caused by the protozoan parasite Trypanosoma cruzi. There is no current effective treatment since the only two available drugs have a limited efficacy and produce side effects.
Benaim, Gustavo +4 more
core +1 more source
From Synthesis to Therapeutics: Bioactive‐Coated Zein Nanoparticles in Drug Delivery
ABSTRACT Polymeric zein nanoparticles (ZNP), derived from corn protein, are biodegradable drug carriers with high stability and low synthesis costs. Their amphiphilic nature allows efficient encapsulation of both hydrophilic and lipophilic drugs, making them promising for drug delivery.
Milena Ferreira de Lima +8 more
wiley +1 more source

